Congress finally reauthorized the Rare Pediatric Disease Priority Review Voucher program, after it expired in 2024. That matters a lot to patients and drug developers, writes George Magrath, M.D.
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- Why 'Be Your Authentic Self' Is Actually Bad Advice
- A Serial Biotech Entrepreneur's Recipe For Success
- From Lab To Launch: Navigating The Transition To Commercial Readiness
- Visibility Without Discoverability: A Life Sciences Marketing Challenge
- Building Biotech's Future: The Strategic Imperative Of AI Integration
- FDA Further Expands And Clarifies Expanded Access FAQs
- Your Microbiome Might Be Trying To Tell You Something
COMPANIES TO WATCH
-
![Adam Mendelsohn_Vivani]( "Companies To Watch: Vivani Medical")
Companies To Watch: Vivani MedicalVivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.
-
![Stacy Lindborg_Imunon]( "Companies To Watch: Imunon")
Imunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
![Tim Lu_Senti Bio]( "Companies To Watch: Senti Bio")
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
![Amy Burroughs_Terns Pharmaceuticals]( "Companies To Watch: Terns Pharmaceuticals")
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
WHERE ARE THEY NOW
-
![Bobak Azamian]( "Where Are They Now? Tarsus Pharmaceuticals")
Where Are They Now? Tarsus PharmaceuticalsTarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
![Teva Cover]( "Where Are They Now? Teva Pharmaceuticals")
Where Are They Now? Teva PharmaceuticalsTeva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 02.06.26 -- Corporate Spin-Offs And NewCos: Unlocking Value In Biopharma Innovation
- 02.06.26 -- New Podcast Episodes: Putting Pressure On CDMOs, BoB@JPM, Building Safer CRISPR Medicines For CVD
- 02.04.26 -- Why 'Be Your Authentic Self' Is Actually Bad Advice
- 02.02.26 -- BoB@JPM: Ron Cooper, enGene
- 01.30.26 -- A Serial Biotech Entrepreneur's Recipe For Success
SPOTLIGHT
Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.
